MX2021009799A - Formulacion de afabicin, metodo para elaborar la misma. - Google Patents
Formulacion de afabicin, metodo para elaborar la misma.Info
- Publication number
- MX2021009799A MX2021009799A MX2021009799A MX2021009799A MX2021009799A MX 2021009799 A MX2021009799 A MX 2021009799A MX 2021009799 A MX2021009799 A MX 2021009799A MX 2021009799 A MX2021009799 A MX 2021009799A MX 2021009799 A MX2021009799 A MX 2021009799A
- Authority
- MX
- Mexico
- Prior art keywords
- afabicin
- making
- formulation
- same
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona composiciones farmacéuticas sólidas que contienen Afabicin que presentan características de disolución superiores. Este efecto beneficioso se logra mediante la presencia de un compuesto de histidina para fabricar las composiciones. La presente invención proporciona además métodos para preparar tales composiciones y usos de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157255 | 2019-02-14 | ||
PCT/EP2020/053882 WO2020165407A1 (en) | 2019-02-14 | 2020-02-14 | Afabicin formulation, method for making the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009799A true MX2021009799A (es) | 2021-09-08 |
Family
ID=65440901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009799A MX2021009799A (es) | 2019-02-14 | 2020-02-14 | Formulacion de afabicin, metodo para elaborar la misma. |
Country Status (27)
Country | Link |
---|---|
US (1) | US20220142993A1 (es) |
EP (1) | EP3923914B1 (es) |
JP (1) | JP7383715B2 (es) |
KR (1) | KR20210127187A (es) |
CN (2) | CN116327781A (es) |
AU (1) | AU2020223515A1 (es) |
BR (1) | BR112021015825B1 (es) |
CA (1) | CA3129508A1 (es) |
CL (1) | CL2021002149A1 (es) |
CY (1) | CY1126077T1 (es) |
DK (1) | DK3923914T3 (es) |
EA (1) | EA202192246A1 (es) |
ES (1) | ES2944535T3 (es) |
FI (1) | FI3923914T3 (es) |
HR (1) | HRP20230437T1 (es) |
HU (1) | HUE062061T2 (es) |
IL (1) | IL285204A (es) |
LT (1) | LT3923914T (es) |
MA (1) | MA54009B1 (es) |
MX (1) | MX2021009799A (es) |
PL (1) | PL3923914T3 (es) |
PT (1) | PT3923914T (es) |
RS (1) | RS64158B1 (es) |
SG (1) | SG11202108591PA (es) |
SI (1) | SI3923914T1 (es) |
TN (1) | TN2021000159A1 (es) |
WO (1) | WO2020165407A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022515775A (ja) | 2018-12-21 | 2022-02-22 | アクルクス ファーマシューティカルズ エルエルシー | Dnaポリメラーゼiiic阻害剤及びその使用 |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2444597A1 (en) | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
CN101415701A (zh) * | 2005-12-05 | 2009-04-22 | Affinium医药公司 | 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂 |
JP6085026B2 (ja) | 2012-06-19 | 2017-02-22 | デビオファーム インターナショナル エスエーDebiopharm International Sa | (e)−n−メチル−n−((3−メチルベンゾフラン−2−イル)メチル)−3−(7−オキソ−5,6,7,8−テトラヒドロ−1,8−ナフチリジン−3−イル)アクリルアミドのプロドラッグ誘導体 |
CA3014541A1 (en) * | 2016-02-26 | 2017-08-31 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
-
2020
- 2020-02-14 LT LTEPPCT/EP2020/053882T patent/LT3923914T/lt unknown
- 2020-02-14 AU AU2020223515A patent/AU2020223515A1/en active Pending
- 2020-02-14 HU HUE20704307A patent/HUE062061T2/hu unknown
- 2020-02-14 ES ES20704307T patent/ES2944535T3/es active Active
- 2020-02-14 RS RS20230315A patent/RS64158B1/sr unknown
- 2020-02-14 EA EA202192246A patent/EA202192246A1/ru unknown
- 2020-02-14 SG SG11202108591PA patent/SG11202108591PA/en unknown
- 2020-02-14 EP EP20704307.6A patent/EP3923914B1/en active Active
- 2020-02-14 MX MX2021009799A patent/MX2021009799A/es unknown
- 2020-02-14 HR HRP20230437TT patent/HRP20230437T1/hr unknown
- 2020-02-14 MA MA54009A patent/MA54009B1/fr unknown
- 2020-02-14 PL PL20704307.6T patent/PL3923914T3/pl unknown
- 2020-02-14 CN CN202310544746.8A patent/CN116327781A/zh active Pending
- 2020-02-14 KR KR1020217028702A patent/KR20210127187A/ko unknown
- 2020-02-14 JP JP2021545458A patent/JP7383715B2/ja active Active
- 2020-02-14 CA CA3129508A patent/CA3129508A1/en active Pending
- 2020-02-14 WO PCT/EP2020/053882 patent/WO2020165407A1/en active Application Filing
- 2020-02-14 BR BR112021015825-1A patent/BR112021015825B1/pt active IP Right Grant
- 2020-02-14 FI FIEP20704307.6T patent/FI3923914T3/fi active
- 2020-02-14 TN TNP/2021/000159A patent/TN2021000159A1/en unknown
- 2020-02-14 CN CN202080014005.3A patent/CN113423390B/zh active Active
- 2020-02-14 DK DK20704307.6T patent/DK3923914T3/da active
- 2020-02-14 SI SI202030183T patent/SI3923914T1/sl unknown
- 2020-02-14 PT PT207043076T patent/PT3923914T/pt unknown
- 2020-02-14 US US17/430,616 patent/US20220142993A1/en active Pending
-
2021
- 2021-07-28 IL IL285204A patent/IL285204A/en unknown
- 2021-08-13 CL CL2021002149A patent/CL2021002149A1/es unknown
-
2023
- 2023-05-09 CY CY20231100220T patent/CY1126077T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK3923914T3 (da) | 2023-05-01 |
FI3923914T3 (fi) | 2023-04-27 |
CA3129508A1 (en) | 2020-08-20 |
LT3923914T (lt) | 2023-07-25 |
CY1126077T1 (el) | 2023-11-15 |
WO2020165407A1 (en) | 2020-08-20 |
RS64158B1 (sr) | 2023-05-31 |
ES2944535T3 (es) | 2023-06-22 |
SG11202108591PA (en) | 2021-09-29 |
SI3923914T1 (sl) | 2023-08-31 |
PL3923914T3 (pl) | 2023-08-07 |
MA54009B1 (fr) | 2022-10-31 |
AU2020223515A1 (en) | 2021-08-19 |
CL2021002149A1 (es) | 2022-03-04 |
HUE062061T2 (hu) | 2023-09-28 |
CN116327781A (zh) | 2023-06-27 |
EP3923914A1 (en) | 2021-12-22 |
US20220142993A1 (en) | 2022-05-12 |
CN113423390B (zh) | 2023-05-23 |
MA54009A1 (fr) | 2022-05-31 |
BR112021015825B1 (pt) | 2024-03-12 |
BR112021015825A2 (pt) | 2021-10-13 |
KR20210127187A (ko) | 2021-10-21 |
HRP20230437T1 (hr) | 2023-07-07 |
IL285204A (en) | 2021-09-30 |
CN113423390A (zh) | 2021-09-21 |
JP2022520170A (ja) | 2022-03-29 |
EP3923914B1 (en) | 2023-04-12 |
EA202192246A1 (ru) | 2021-11-18 |
TN2021000159A1 (en) | 2023-04-04 |
JP7383715B2 (ja) | 2023-11-20 |
PT3923914T (pt) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020097537A3 (en) | Fused ring compounds | |
PH12021500014A1 (en) | Fused ring compounds | |
WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
MX2021005714A (es) | Nuevos compuestos heterociclicos. | |
WO2017175068A8 (en) | Thiazolopyridine derivatives as gpr119 agonists | |
MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
PH12020500446A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
MX2019015744A (es) | Composiciones farmaceuticas. | |
EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
MX2019012454A (es) | Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. | |
EP4327880A3 (en) | Solid state form of ribociclib succinate | |
TN2021000159A1 (en) | Afabicin formulation, method for making the same and uses thereof | |
PH12020550925A1 (en) | Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same. | |
MX2017015812A (es) | Formulaciones farmaceuticas inyectables de lefamulina. | |
MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
EP3459933A3 (en) | Solid forms of a pharmaceutically active compound | |
WO2018096525A3 (en) | Heteroaryl compounds and uses thereof | |
WO2020055359A3 (en) | Oral dosage form of sorafenib tosylate |